Therapeutic Efficacy of Blood-Production Mixture in Treating Anaemia in Pregnancy and Its Effect on RBC, Hb, MCV and FER Levels

Abstract

Abstract: Objective To investigate the efficacy of Shengxuebao mixture in the treatment of anemia during pregnancy and its effects on red blood cell count (RBC), hemoglobin (Hb), mean red blood cell volume (MCV) and serum ferritin (FER) levels. Methods A total of 80 cases of anemia during pregnancy from May 2020 to August 2022 were randomly divided into two groups, 40 cases in each group. The control group was treated with ferrous fumarate, and the experimental group was treated with Shengxuebao mixture. RBC, Hb, MCV and FER levels were detected before and after treatment to evaluate clinical efficacy and safety, and adverse perinatal outcomes were recorded. Results The levels of Hb, RBC, MCV and FER in the two groups were significantly increased after treatment (P<0.05), and the levels of Hb, RBC, MCV and FER in the experimental group were significantly higher than those in the control group after treatment (P<0.05). The clinical effect of experimental group was significantly better than that of control group (P<0.05). There were no significant difference in the incidence of fetal developmental delay, fetal distress, premature delivery, low birth weight and puerperal infection between the two groups (P>0.05). The incidence of adverse reactions in experimental group was 5.00% and 22.50% in control group, and the incidence of adverse reactions in experimental group was significantly lower than that in control group (P<0.05). Conclusion Shengxuebao mixture can improve clinical efficacy and reduce gastrointestinal symptoms caused by iron treatment,and had no effect on maternal and infant outcomes,. It is safe and effective.

Key words: anemia during pregnancy, shengxue bao mixture, ferrous fumarate, anemia index

CLC Number:

R714.25

ZHAO Ju, XUE Liang-yu. Therapeutic Efficacy of Blood-Production Mixture in Treating Anaemia in Pregnancy and Its Effect on RBC, Hb, MCV and FER Levels[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(13): 25-28.

References

[1] 刘晓曦,扆运杰,冯羿凯,等.中国妊娠期贫血流行状况分析[J].中国生育健康杂志,2021,32(3):210-215.
[2] 崔宇童,李笑天.孕期贫血与不良妊娠结局[J].中国实用妇科与产科杂志,2020,36(5):408-412.
[3] RANDALL D A, PATTERSON J A, GALLIMORE F,et al.The association between haemoglobin levels in the first 20 weeks of pregnancy and pregnancy outcomes.[J]. PLoS ONE,2019(11):e0225123.
[4] 杜宝丽,李晓燕,孙琪.妊娠期和产后严重贫血孕产妇不良妊娠结局风险的多水平分析研究[J].中国性科学,2020,29(11):58-63.
[5] 张尧,田亚平,何玺玉,等.遗传代谢病所致贫血的诊疗专家共识[J].标记免疫分析与临床,2021,28(10):1626-1634.
[6] 耿慧珍,王子莲.妊娠期贫血常见病因及诊断[J].中国实用妇科与产科杂志, 2022, 38(12):1156-1159.
[7] 王奋勤,梁娟丽,王苗苗,等.生血宝合剂辅助治疗妊娠期缺铁性贫血效果及对孕妇MCV、SF及妊娠结局影响[J].中国计划生育学杂志,2020,28(7):1053-1055,1063.
[8] 唐凌,杨志玲,王愚.生血宝合剂联合蛋白琥珀酸铁对不同程度妊娠缺铁性贫血血液指标及母儿结局的影响[J].湖北中医药大学学报,2022,24(2):78-80.
[9] 中华医学会围产医学分会.妊娠期铁缺乏和缺铁性贫血诊治指南[J].中华围产医学杂志,2014,14(7):451-454.
[10] 郎海燕,陈信义,杨文华.缺铁性贫血中医药防治康复一体化专家共识[J].中华中医药杂志,2018,33(8):3487-3492.
[11] 张之南. 血液病诊断及疗效标准[M].北京:北京科学技术出版社,1998:10-15.
[12] 毕素娟,王菲,陈秀琴,等.生血宝合剂联合琥珀酸亚铁片治疗妊娠期缺铁性贫血的疗效及对铁代谢指标和妊娠结局的影响[J].现代生物医学进展,2022,22(9):1687-1690,1624.
[13] 马西虎,刘晓,黄志惠.薯蓣丸加味制膏辅助治疗缺铁性贫血的临床效果[J].中国医药导报,2022,19(24):128-131.
[14] 范洪桥,周亮,刘丽芳,等.谭新华从“形精气味”论治乳腺癌相关性贫血经验[J].中国中医药信息杂志,2021,28(1):125-127.
[15] 齐利丽,何苗,朱丽红,等.中西医结合治疗妊娠合并缺铁性贫血的Meta分析[J].山东中医杂志,2020,39(7):669-677,683.
[16] 王金环,张丽琴,雍彦礼,等.孙伟正教授应用“补脾益肾,酸甘化血”法治疗缺铁性贫血经验[J].中医药学报,2020,48(10):56-59.
[17] 聂取,王洪新.基于TLR4/NF-κB通路探讨黄芪甲苷对炎症性贫血的改善作用[J].中国中医药科技,2020,27(4):542-546.
[18] 叶先文,邓亚羚,任洪民,等.基于网络药理学探讨白芍治疗贫血的机制[J].中成药,2021,43(3):796-802.
[19] 温国华,李燕玲.生血宝合剂对吉西他滨联合顺铂化疗发生的骨髓抑制患者的疗效观察[J].山西医药杂志,2021,50(24):3358-3360.
[20] 蔡智慧,田肖芳,李蕾,等.聚乙二醇化重组人粒细胞集落刺激因子联合生血宝合剂预防恶性肿瘤化疗后骨髓抑制的临床观察[J].广西医学,2020,42(1):21-23.
[21] 牧亚峰,向楠,左新河,等.白芍总苷对自身免疫性甲状腺炎大鼠肠黏膜屏障及肠道菌群的影响[J].中草药,2021,52(11):3269-3277.
[22] 哈小琴,杨志华,白燕清,等.黄芪多糖联合TPHK对低氧水浸复合应激致大鼠胃肠道损伤的防护作用[J].西北国防医学杂志,2021,42(6):423-430.